Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;22(2):152-156.
doi: 10.1055/s-0037-1605596. Epub 2017 Aug 28.

The Role of the Level of Interleukin-33 in the Therapeutic Outcomes of Immunotherapy in Patients with Allergic Rhinitis

Wail Fayez Nasr  1 , Samir Sorour Sorour  1 , Atef Taha El Bahrawy  1 , Ghada Samir Boghdadi  2 , Alia A El Shahaway  2
Affiliations

The Role of the Level of Interleukin-33 in the Therapeutic Outcomes of Immunotherapy in Patients with Allergic Rhinitis

Wail Fayez Nasr et al. Int Arch Otorhinolaryngol. 2018 Apr.

Abstract

Introduction Allergic rhinitis (AR) affects up to 40% of the population and results in nasal itching, congestion, sneezing, and clear rhinorrhea. Objectives This study aimed to evaluate the changes in the clinical symptoms and in the level of serum interleukin (IL)-33 before and after pollen immunotherapy (IT) in patients with AR. Methods The total symptom score and the levels of total immunoglobulin E (IgE) and IL-33 were determined in the serum of 10 non-allergic healthy controls and 45 patients with AR who were equally divided into 3 groups: GI (patients did not receive IT), GII (patients had received IT for 6 months) and GIII (patients had received IT for 2 years). Results There was a significantly higher concentration of IgE and IL-33 in the serum of patients with AR than in that of non-allergic patients. Furthermore, serum level of IL-33 decreased significantly after pollen IT. But, there was no significant reduction in the serum level of IL-33 between GII and GIII patients. Conclusion Our results show a clinical improvement associated with a decrease in serum level of IL-33 after pollen IT.

Keywords: allergen immunotherapy; allergic rhinitis; helper T cells; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors report no conflict of interest.

Figures

Fig. 1
Fig. 1
Shows clinical improvement of nasal symptoms in AR patients in response to immunotherapy.
Fig. 2
Fig. 2
Shows reduction in serum IL-33 levels in AR patients with immunotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Uzzaman A, Story R. Chapter 5: Allergic rhinitis. Allergy Asthma Proc. 2012;33 01:S15–S18. - PubMed
    1. Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. Immunol Allergy Clin North Am. 2011;31(03):561–599. - PubMed
    1. Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol. 2012;158 01:47–50. - PubMed
    1. Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res. 2012;61(06):547–550. - PMC - PubMed
    1. Schatz M, Meltzer E O, Nathan R et al.Psychometric validation of the rhinitis control assessment test: a brief patient-completed instrument for evaluating rhinitis symptom control. Ann Allergy Asthma Immunol. 2010;104(02):118–124. - PubMed